VEGFA and diabetes mellitus: The administration of the nitric oxide (NO) synthase inhibitor L-NAME for extended periods of time may inhibit endothelial NO synthesis, damage vascular endothelial function, and induce the expression of cytokines including VEGF in order to study animal models of type 2 diabetes mellitus and their large vascular lesions [15, 16].